Henry Schein upgraded to Outperform from Neutral at Baird

Baird upgraded Henry Schein (HSIC) to Outperform from Neutral with a price target of $100, up from $78. The firm believes the bias across its dental names remains to the upside. Henry Schein’s setup is “feeling improved,” the analyst tells investors in a research note. Baird’s February dental survey points to a third straight month of modest rebound in patient demand.